Otonomy drug flunks Phase IIb: full speed ahead to Phase III
This article was originally published in Scrip
Executive Summary
Otonomy saw its share price plummet by nearly 18% in after-hours trading on 21 May after it announced that its investigational treatment OTO-104 for Ménière's disease had failed a Phase IIb trial. That a range of secondary endpoints were met and the company's decision to move it into Phase III based on the data evidently failed to settle investors' nerves.
You may also be interested in...
What Does 2020 Hold For Biopharma?
Previewing the year to come, our journalists contacted more than 80 industry executives and experts for their views on what 2020 could hold for the biopharma sector. A series of articles based on these discussions were published by In Vivo’s sister publication Scrip. The following are highlights of the key issues that are top of mind for industry leaders this year, including digital tools, advanced therapies, the US election and manufacturing.
Scrip Asks… What Does 2020 Hold For Biopharma? Part 4: The Patient
From the general to the particular: drug developers are increasingly tailoring therapies to individuals. Driven by important advances in understanding biology as well as new tools to harness big data, industry participants expect significant progress in biopharma’s approach to the patient.
Scrip Asks…What Does 2020 Hold For Biopharma? Part 3: Policy And Regulation
The US election will intensify the spotlight on drug costs, regulators will have their hands full with advanced therapy filings, and the need to address rising infectious disease threats will mount. Biosimilars, cannabis and Brexit are among other hot topics for 2020.
Need a specific report? 1000+ reports available
Buy Reports